{"protocolSection":{"identificationModule":{"nctId":"NCT02550717","orgStudyIdInfo":{"id":"18116"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)","officialTitle":"A Pharmacoepidemiological Study on the Risk of Bleeding in New Users of Low-dose Aspirin (ASA) in The Health Improvement Network (THIN), UK","acronym":"EPISAT"},"statusModule":{"statusVerifiedDate":"2018-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-09-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-03-31","type":"ACTUAL"},"completionDateStruct":{"date":"2017-03-31","type":"ACTUAL"},"studyFirstSubmitDate":"2015-09-03","studyFirstSubmitQcDate":"2015-09-14","studyFirstPostDateStruct":{"date":"2015-09-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-10-23","lastUpdatePostDateStruct":{"date":"2018-10-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To investigate the risk of major bleeding (including gastrointestinal and intracranial bleeding episodes) among new users of low-dose acetylsalicylic acid (ASA) in clinical practice","detailedDescription":"These will be based on population-based cohorts using data from a primary care database in the UK: The Health Improvement Network (THIN) and will serve to make a clinically meaningful benefit-risk assessment regarding major bleeding consequences of ASA exposure in general population."},"conditionsModule":{"conditions":["Secondary Prevention","Stroke","Ischemic Heart Disease","Coronary Heart Disease"],"keywords":["Low-dose Acetylsalicylic Acid,","Bleeding,","The Health Improvement Network (THIN),","Cardiovascular","Secondary prevention of cardiovascular events"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":398158,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Acetylsalicylic Acid","description":"New users of low-dose Acetylsalicylic Acid (ASA)","interventionNames":["Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)"]},{"label":"Other medications","description":"Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)","interventionNames":["Drug: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs"]}],"interventions":[{"type":"DRUG","name":"Acetylsalicylic Acid (Aspirin, BAYE4465)","description":"Low-dose ASA for secondary prevention of cardiovascular events","armGroupLabels":["Acetylsalicylic Acid"]},{"type":"DRUG","name":"Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs","description":"Secondary prevention of cardiovascular events","armGroupLabels":["Other medications"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Intracranial bleeding among new users of low-dose Acetylsalicylic acid (ASA).","timeFrame":"Up to 13 years"},{"measure":"Incidence of Upper gastrointestinal bleeding among new users of low-dose ASA.","timeFrame":"Up to 13 years"},{"measure":"Incidence of Lower gastrointestinal bleeding among new users of low-dose ASA","timeFrame":"Up to 13 years"},{"measure":"Time to Intracranial bleeding among new users of low-dose ASA","timeFrame":"Up to 13 years"},{"measure":"Time to Upper gastrointestinal bleeding among new users of low-dose ASA","timeFrame":"Up to 13 years"},{"measure":"Time to Lower gastrointestinal bleeding among new users of low-dose ASA","timeFrame":"Up to 13 years"},{"measure":"Relative risk of Intracranial bleeding among new users of low dose ASA","description":"Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.","timeFrame":"Up to 13 years"},{"measure":"Relative risk of Upper gastrointestinal bleeding among new users of low-dose ASA","description":"Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.","timeFrame":"Up to 13 years"},{"measure":"Relative risk of Lower gastrointestinal bleeding among new users of low-dose ASA","description":"Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.","timeFrame":"Up to 13 years"}],"secondaryOutcomes":[{"measure":"Relative risk of Intracranial bleeding associated with use of other medications.","description":"Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.To estimate relative risk in users of other medications such as clopidogrel,oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs), independently from use of low-dose ASA and concomitantly","timeFrame":"Up to 13 years"},{"measure":"Relative risk of Upper gastrointestinal bleeding associated with use of other medications","description":"Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.To estimate relative risk in users of other medications such as clopidogrel,oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs), independently from use of low-dose ASA and concomitantly","timeFrame":"Up to 13 years"},{"measure":"Relative risk of Lower gastrointestinal bleeding associated with use of other medications.","description":"Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.To estimate relative risk in users of other medications such as clopidogrel,oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs), independently from use of low-dose ASA and concomitantly","timeFrame":"Up to 13 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 40-84 years\n* Enrolled with the Primary Care Physician (PCP) for at least 2 years,\n* To have a history of computerized prescriptions for at least 1 year prior\n* To have at least one encounter/visit recorded in the last three years\n\nExclusion Criteria:\n\n* To be exposed to low dose ASA before entering in the study\n* Having a diagnosis of cancer before entering in the study\n* Having a diagnosis of alcohol abuse before entering in the study\n* Having a diagnosis of coagulopathies before entering in the study\n* Having a diagnosis of esophageal varices before entering in the study\n* Having a diagnosis of chronic liver disease before entering in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"84 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"THIN is a computerized medical research database that contains systematically recorded data on more than 3 million UK primary care patients. It is representative of this population with regard to age, sex, and geographic distribution, and has been validated for use in pharmacoepidemiological and epidemiological research in multiple studies 13. Participating Primary Care Physicians (PCPs) record prospectively data as part of their routine patient care, including demographics and life style factors (e.g. alcohol use, body mass index (BMI) and smoking status), consultation rates, referrals, hospital admissions, laboratory test results, diagnoses, prescriptions ordered by the PCPs, and a free text section, and send their data anonymously to THIN for use in research projects.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Multiple Locations","country":"United Kingdom"}]},"referencesModule":{"references":[{"pmid":"29093065","type":"RESULT","citation":"Cea Soriano L, Gaist D, Soriano-Gabarro M, Bromley S, Garcia Rodriguez LA. Low-dose aspirin and risk of intracranial bleeds: An observational study in UK general practice. Neurology. 2017 Nov 28;89(22):2280-2287. doi: 10.1212/WNL.0000000000004694. Epub 2017 Nov 1."},{"pmid":"28371181","type":"RESULT","citation":"Cea Soriano L, Gaist D, Soriano-Gabarro M, Garcia Rodriguez LA. Incidence of intracranial bleeds in new users of low-dose aspirin: a cohort study using The Health Improvement Network. J Thromb Haemost. 2017 Jun;15(6):1055-1064. doi: 10.1111/jth.13686. Epub 2017 May 2."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000006331","term":"Heart Diseases"},{"id":"D000003327","term":"Coronary Disease"},{"id":"D000003324","term":"Coronary Artery Disease"},{"id":"D000017202","term":"Myocardial Ischemia"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","asFound":"Ischemic Heart Disease","relevance":"HIGH"},{"id":"M6239","name":"Coronary Disease","asFound":"Coronary Heart Disease","relevance":"HIGH"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M19196","name":"Myocardial Ischemia","asFound":"Ischemic Heart Disease","relevance":"HIGH"},{"id":"M9109","name":"Heart Diseases","asFound":"Heart Disease","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Barriers","relevance":"HIGH"},{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","asFound":"Domains","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M15202","name":"Serotonin","relevance":"LOW"},{"id":"M19339","name":"Selective Serotonin Reuptake Inhibitors","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"}]}},"hasResults":false}